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Summary
Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1
(XPO1, also termed CRM1). Non-clinical studies support combining seli-
nexor with proteasome inhibitors (PIs) and corticosteroids to overcome
resistance in relapsed/refractory multiple myeloma (RRMM). We con-
ducted a phase I dose-escalation trial of twice-weekly selinexor in combina-
tion with carfilzomib and dexamethasone (SKd) to determine maximum
tolerated dose in patients with RRMM (N = 21), with an expansion cohort
to assess activity in carfilzomib-refractory disease and identify a recom-
mended phase II dose (RP2D). During dose escalation, there was one dose-
limiting toxicity (cardiac failure). The RP2D of twice-weekly SKd was seli-
nexor 60 mg, carfilzomib 20/27 mg/m2 and dexamethasone 20 mg. The
most common grade 3/4 treatment-emergent adverse events included
thrombocytopenia (71%), anaemia (33%), lymphopenia (33%), neutrope-
nia (33%) and infections (24%). Rates of ≥minimal response, ≥partial
response and very good partial response were 71%, 48% and 14%, respec-
tively; similar response outcomes were observed for dual-class refractory
(PI and immunomodulatory drug)/quad-exposed (carfilzomib, bortezomib,
lenalidomide and pomalidomide) patients (n = 17), and patients refractory
to carfilzomib in last line of therapy (n = 13). Median progression-free sur-
vival was 37 months, and overall survival was 224 months in the overall
population. SKd was tolerable and re-established disease control in RRMM
patients, including carfilzomib-refractory patients.
Registered at ClinicalTrials.gov (NCT02199665)
Keywords: relapsed/refractory multiple myeloma, selinexor, carfilzomib,
dexamethasone.
The development of immunomodulatory drugs (IMiDs; e.g.
lenalidomide, pomalidomide) and proteasome inhibitors
(PIs; e.g. carfilzomib, bortezomib) as standards of care for
patients with multiple myeloma (MM) has resulted in signifi-
cant improvements in survival (Brenner et al, 2009; Kumar
et al, 2008; Thumallapally et al, 2016). However, nearly all
patients require multiple lines of therapy as they relapse or
develop disease refractory to treatment. First-line and subse-
quent therapies usually involve IMiDs and PIs in doublet or
triplet combinations with corticosteroids and other systemic
therapies (Kumar et al, 2018). As use of these combinations
have become new standards of care, the treatment challenges
in the relapsed/refractory (RR) setting have evolved, with
increasing numbers of patients being quad-refractory to
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bortezomib, lenalidomide, pomalidomide and carfilzomib or
penta-refractory to these four drugs and the anti-CD38 mon-
oclonal antibody daratumumab. There is a need to develop
agents with novel mechanisms of action to overcome treat-
ment resistance (Chim et al, 2018; Sonneveld & Broijl, 2016).
Selinexor is an oral Selective Inhibitor of Nuclear Export
that targets Exportin 1 (XPO1, also termed CRM1), the only
known nuclear export protein for tumour suppressor pro-
teins (TSPs) and cell-cycle regulators (e.g. p53, FOXO, IjB,
p21, p27), as well as eukaryotic translation initiation factor
4E (eIF4E)-bound oncoprotein mRNAs (Conforti et al, 2015;
Culjkovic-Kraljacic et al, 2012; Das et al, 2015; Gravina et al,
2014). Overexpression of XPO1 is essential for MM cell sur-
vival (Schmidt et al, 2013; Tiedemann et al, 2012). XPO1
mediates the functional inactivation of cell-cycle regulators
and TSPs and promotes the export and translation of mRNA
for key oncoproteins, including c-MYC, BCL-2 and Cyclin D
(Culjkovic-Kraljacic et al, 2012; Gandhi et al, 2018; Nguyen
et al, 2012). Inhibition of XPO1 with selinexor restores
nuclear localization of TSPs and cell-cycle regulators (Nair
et al, 2017; Tai et al, 2014). Selinexor elevates levels of the
inhibitor of kappa B (IjBa), which forms complexes with
and inhibits transcription factor nuclear factor (NF)jB, dis-
rupting a range of signalling pathways, including inflamma-
tion, oncogenesis and cell survival. In myeloma cells,
selinexor treatment has been shown to induce apoptosis,
reduce levels of proto-oncoproteins and impair osteoclasto-
genesis (Das et al, 2015; Schmidt et al, 2013; Tai et al, 2014).
Preclinical studies have provided a rationale for combining
selinexor with PIs (Kashyap et al, 2016; Nair et al, 2017;
Rosebeck et al, 2016; Turner et al, 2016). The addition of
selinexor to a PI has a synergistic effect on cell death of mye-
loma cell lines and primary plasma cells derived from
patients with RRMM, and the combination demonstrated
greater antimyeloma activity in a murine xenograft model
than either agent alone (Kashyap et al, 2016; Rosebeck et al,
2016; Turner et al, 2016). Selinexor-PI combinations were
associated with inhibition of BCL2 expression, increased
cleavage and inactivation of AKT, activation of caspase-10
and other caspases, and increased levels of IjBa and IjBa-
NFjB complexes, leading to neutralization of NF-jB
(Kashyap et al, 2016; Rosebeck et al, 2016; Turner et al,
2016). NF-jB activation has been shown to be a mechanism
of PI resistance (L€u & Wang, 2013; Markovina et al, 2008).
The clinical activity of selinexor as a single agent and as
part of combination regimens has been demonstrated in
heavily pre-treated patients with RRMM (Chen et al, 2018;
Vogl et al, 2018). Single-agent selinexor was associated with
modest activity in a phase I study with an objective response
rate (ORR) of 4%, which improved to 50% when selinexor
was combined with dexamethasone (Sd) at the twice-weekly
recommended phase 2 dose (RP2D) (Chen et al, 2018). In
the subsequent phase II STORM study, the Sd combination
generated ORRs of 21% for patients with quad-refractory
MM and 20% in penta-refractory patients (Vogl et al, 2018).
The addition of selinexor to bortezomib and dexamethasone
(SVd) in the phase I/II STOMP study generated ORRs of
43% in a cohort with PI-refractory RRMM (Bahlis et al,
2018).
Carfilzomib is approved for use in combination with dex-
amethasone for patients with RRMM (Berenson et al, 2014;
Dimopoulos et al, 2016a; Siegel et al, 2012). Preclinical stud-
ies have demonstrated synergistic activity between selinexor
and carfilzomib (Kashyap et al, 2016; Rosebeck et al, 2016;
Turner et al, 2016), and clinical studies further support
carfilzomib as a potential therapeutic partner in RRMM.
Carfilzomib was active in patients with MM previously trea-
ted with or refractory to bortezomib (Berenson et al, 2016,
2014), and the combination of carfilzomib and dexametha-
sone (Kd) demonstrated improved progression-free survival
(PFS) and overall survival (OS) compared with the combina-
tion of bortezomib and dexamethasone (Vd) in patients with
RRMM (Dimopoulos et al, 2017, 2016a). Here we describe a
phase 1 multicentre, open-label, investigator-initiated study
to determine the maximum tolerated dose (MTD) and the
RP2D of twice-weekly selinexor in combination with Kd in
patients with RRMM, as well as safety, tolerability and pre-
liminary efficacy.
Methods
Study design
This is a multicentre, open-label, phase I study (ClinicalTri-
als.gov, NCT02199665). The primary objectives were to
determine the MTD for the combination of twice-weekly
selinexor with Kd (SKd) in patients with RRMM, employing
a 3 + 3 dose escalation design, followed by an expansion
cohort to support a RP2D. Secondary objectives were to
determine safety, tolerability and efficacy.
Patients aged ≥18 years with progressive RRMM were
enrolled at five Multiple Myeloma Research Consortium sites
in North America. Patients were eligible provided they had
been previously treated with at least two anti-myeloma thera-
pies, including a PI and an IMiD, had an absolute neutrophil
count ≥10 9 109/l, a haemoglobin concentration ≥80 g/l, a
platelet count ≥50 9 109/l and adequate hepatic (total biliru-
bin ≤2 times the upper limit of normal and alanine amino-
transferase ≤25 times the upper limit of normal) and renal
function (creatinine clearance ≥30 ml/min) within 14 days of
treatment initiation. Patients were excluded if they had
received prior selinexor or any other anticancer therapy
within 2 weeks of treatment initiation. Concurrent anticancer
therapy other than steroids was not allowed. Other exclusion
criteria included unstable angina or myocardial infarction
within 4 months of treatment initiation, New York Heart
Association Class III/IV congestive heart failure, left ventricu-
lar ejection fraction <40%, history of severe coronary artery
disease, severe uncontrolled ventricular arrhythmias or
uncontrolled hypertension or uncontrolled diabetes within
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14 days of treatment initiation. Patients with plasma cell leu-
kaemia, Waldenstr€om macroglobulinaemia, POEMS
(polyneuropathy, organomegaly, endocrinopathy, monoclonal
protein, skin changes) syndrome or amyloidosis were also
excluded.
The study was conducted in accordance with US Food
and Drug Administration and International Conference on
Harmonisation Guidelines for Good Clinical Practice, the
Declaration of Helsinki, Health Canada, and any applicable
local health authority, institutional review board or ethics
committee requirements. All patients provided written
informed consent.
Schedule and dosing
For the dose-escalation phase, three patients were assigned to
each cohort, beginning at Dose Level 1 (Fig 1). Selinexor,
carfilzomib and dexamethasone were all administered twice
weekly, and both selinexor and carfilzomib doses were esca-
lated. Beginning at Dose Level 1, if none of the first three
patients enrolled into the cohort experienced a dose-limiting
toxicity (DLT), then dose escalation proceeded to the next
cohort. If any one of the three patients experienced a DLT,
three more patients were added to the cohort at the same
dose. If there were no additional DLTs, dose escalation pro-
ceeded to the next cohort. If two or more DLTs were
observed among the initial three or expanded six patients,
the dose level was considered to exceed the MTD. Because
there were delays in patient accrual, the study protocol was
amended to ensure that eligible patients could enrol at the
time of their availability—expansion to six patients per
cohort was allowed if, at a given dose level, three patients
were enrolled and no DLTs were observed but all three had
not completed their first cycle of treatment. Patients who did
not receive all scheduled doses (unrelated to drug toxicity)
during Cycle 1 were replaced for DLT evaluation per the
study protocol. Given that our patients were heavily pre-trea-
ted with advanced disease, we anticipated that disease-related
sequalae might prevent patients from completing the dose-
escalation phase without dose interruption.
Once the MTD or maximum recommend dose was deter-
mined, that dose cohort was to be expanded to a total of 12
carfilzomib-refractory patients as defined by the International
Myeloma Working Group (IMWG) criteria (Rajkumar et al,
2011). If the overall DLT rate for this cohort was <30%, this
dose would be declared the RP2D.
All patients received herpes zoster virus prophylaxis (e.g.
valacyclovir) and prophylactic anti-emetic therapy with
megesterol acetate (160–400 mg daily) and a 5-hydrox-
ytryptamine-3 (5-HT3) antagonist.
Assessments
Safety and tolerability were evaluated by means of drug-re-
lated DLTs in the dose-escalation cohorts, treatment-
emergent adverse events (AEs), physical examinations and
laboratory tests. DLTs were prespecified haematological and
non-haematological toxicities that were considered treat-
ment-related and occurred during Cycle 1. Haematological
DLTs were: febrile neutropenia; grade 4 neutropenia lasting
>7 days; grade 4 thrombocytopenia lasting >7 days despite
dose delay; and grade 3/4 thrombocytopenia associated with
bleeding. Non-haematological DLTs were: grade ≥2 neuropa-
thy and any grade ≥3 toxicity (lasting for ≥3 days for gas-
trointestinal events and >7 days for fatigue or anorexia)
despite maximal supportive care except for electrolyte abnor-
malities, hair loss and elevation of alanine aminotransferase
or aspartate aminotransferase. Dose modifications were
allowed, but any treatment toxicities that required a dose
reduction during Cycle 1, or any toxicities that delayed initi-
ation of Cycle 2 by >7 days were also considered DLTs.
Treatment-emergent AEs were graded according to the
National Cancer Institute-Common Terminology Criteria for
Adverse Events v4.0 (National Cancer Institute 2010).
Patients that discontinued treatment underwent a final
assessment at 28 days after the last dose of a study drug.
Patients were followed for survival for up to 2 years after the
end of treatment.
Efficacy measures included response according to the
IMWG criteria (Durie et al, 2006; Rajkumar et al, 2011)—
progressive disease (PD), stable disease (SD), minimal
response (MR), partial response (PR), very good partial
response (VGPR), complete response (CR) and stringent
complete response (sCR). Response assessments were com-
pleted at Cycle 2 Day 1 and Day 1 of subsequent cycles. All
response criteria required confirmation with two consecutive
assessments.
Statistical analysis
Continuous and categorical variables were summarized with
descriptive statistics. ORR (≥PR) and a clinical benefit rate
(CBR; ≥MR) were estimated, and 90% confidence intervals
(CIs) were generated for the RP2D cohort. If the data devi-
ated strongly from normality as judged by boxplots and nor-
mal probability plots, non-parametric, Wilcoxon signed-rank
tests were performed in place of t-tests. Given the small sam-
ple size, multiplicity adjustments were not made to the alpha
levels; these analyses were considered exploratory and
hypothesis-generating only. Time-to-event endpoints were
assessed by the Kaplan–Meier method using GraphPad Prism
7.03 software (La Jolla, CA, USA).
Results
Twenty-one patients with RRMM were enrolled between July
2014 and September 2016. The data cut-off for this analysis
was 1 September 2017. Patients were aged between 55 and
74 years, 43% were ≥65 years of age (Table I). The median
time since the initial MM diagnosis was 45 years. Twelve
Selinexor, Carfilzomib and Dexamethasone for RRMM
ª 2019 British Society for Haematology and John Wiley & Sons Ltd 551
British Journal of Haematology, 2019, 186, 549–560
(57%) patients were identified as high risk per IMWG crite-
ria, including 5 (24%) with del (17p). Patients received a
median of 4 (range, 2–10) prior lines of therapy. Previous
treatments included carfilzomib (95%) and pomalidomide
(81%) (Table II). All patients (100%) were refractory to last
line of therapy, including 13 (62%) who were refractory to
carfilzomib (4 to carfilzomib/dexamethasone, 9 to carfil-
zomib/pomalidomide/dexamethasone). Seventeen (81%)
patients were dual-class refractory (refractory to a PI and an
IMiD) and quad-exposed (bortezomib, carfilzomib, lenalido-
mide and pomalidomide). Baseline characteristics and prior
therapies by dose level are presented in Tables SI and SII.
Of the 21 patients enrolled, 18 were evaluable for DLTs
(received one full course of treatment or stopped treatment
due to a DLT). All 21 patients were included in overall toxic-
ity, survival and response assessments. One patient with a
history of congestive heart failure (CHF) was retrospectively
determined to be ineligible due to pre-existing amyloidosis
which was unknown at study entry. This patient enrolled in
the dose-escalation phase of the study and was included in
safety and efficacy assessments.
At data cut-off, the median duration of treatment was 4
cycles (range, 1–14 cycles), with 20 (95%) patients complet-
ing at least 1 cycle and 11 (52%) completing at least 4 cycles.
Twenty patients discontinued the study due to disease pro-
gression (17 [81%]), patient or physician’s choice (1 [5%])
and treatment toxicities (2 [10%]).
Determination of the MTD
During the course of Cycle 1, there were no DLTs at Dose
Level 1 (30 mg/m2 selinexor; 20/27 mg/m2 carfilzomib;
20 mg dexamethasone). Two patients in the Dose Level 1
cohort did not receive all scheduled treatment doses (i.e.
dose modifications unrelated to toxicity) and were replaced
per the study protocol, resulting in a total of five patients in
this cohort. There were no DLTs in three patients enrolled at
Dose Level 2a (40 mg selinexor; 20/36 mg/m2 carfilzomib;
28-day cycles
1
SEL SEL
CFZ
dex
SEL SEL
CFZCFZ CFZ
dex
CFZ
dex dex dex
SEL SEL
dex dex
CFZ
dex
2 3 8 9 10 15
Cycles 1–4
Cycles 5–8: dex reduced from initial 40 mg/w k to 20 mg/w k
Cycles 9+: CFZ administered on days 1, 2 and 15, 16
16 17 22 23 28
Dose Level*†
−2
−1
1
2a
2b
3
4
5
Selinexor
20 mg
20 mg
30 mg/m2
40 mg
60 mg
60 mg
60 mg
60 mg
Carfilzomib‡
20 mg/m2
20/27 mg/m2
20/27 mg/m2
20/36 mg/m2
20/27 mg/m2
20/36 mg/m2
20/45 mg/m2
20/56 mg/m2
Dexamethasone
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
20 mg (C1–4)
10 mg (C5+)
Fig 1. Treatment schema. *Once the Maximum Tolerated Dose was established, an expansion cohort of 6–12 patients was enrolled at that dose
limited to carfilzomib-refractory patients. †Dose Level 2a and 2b were enrolled simultaneously, alternating patients between the two dose levels.
‡Carfilzomib initiated at 20 mg/m2 on Days 1–2 of Cycle 1 at all dose levels and then at the assigned dose level for the remainder of treatment.
C, cycle; CFZ, carfilzomib; dex, dexamethasone; SEL, selinexor.
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20 mg dexamethasone). A DLT was experienced by one of
the first three patients enrolled at Dose Level 2b (60 mg seli-
nexor; 20/27 mg/m2 carfilzomib; 20 mg dexamethasone); the
patient with a history of CHF who retrospectively was found
to have cardiac amyloidosis experienced cardiac failure dur-
ing Cycle 1. Therefore, three additional patients were
assigned to the cohort. One patient did not receive all sched-
uled doses (unrelated to toxicity) and was replaced, resulting
in a total of seven patients for Dose Level 2b, with no addi-
tional DLTs during the dose escalation stage.
Further dose escalation was not pursued based on AE
rates, tolerability and anti-myeloma activity. Assessment by
dose level showed rapid disease control at all dose levels but
no notable trend in the rate or depth of response to support
further escalation, while rates of some AEs increased after
Cycle 1, as did dose reduction. In the safety population, the
rate of grade 3/4 anaemia was 5% during Cycle 1 but
increased to 33% after Cycle 1. In the dose escalation
cohorts, dose reductions were required by 80% (4/5) of
patients enrolled at Dose Level 1, 100% (3/3) at Dose Level
2A, and 29% (2/7) at Dose Level 2b (Table SIII). Based on
these findings and previous experience with selinexor (Bahlis
et al, 2018; Chen et al, 2018; Vogl et al, 2018), Dose Level 2b
was selected as the maximum recommended dose and
selected for expansion. Six additional patients were enrolled
into the Dose Level 2b cohort for a total of 13 patients, of
whom 12 were carfilzomib-refractory. Among these 6
patients, there were 2 DLTs during Cycle 1 (grade 3 diar-
rhoea and grade 3 decrease in platelet count), yielding a DLT
rate of 25% for the 12 patients who completed 1 cycle of
Dose Level 2b (below the predefined limit of 30%). Dose
Level 2b was selected as the RP2D.
Safety
In the 21 enrolled patients, the most commonly observed
treatment-emergent adverse events (TEAEs) of any grade
were thrombocytopenia (81%), fatigue (81%) and anaemia
(71%). The most frequently observed grade 3/4 haematologi-
cal TEAEs were thrombocytopenia (71%), anaemia (33%),
lymphopenia (33%) and neutropenia (33%), and the most
common grade 3/4 non-haematological TEAEs included
infections (24%), fatigue (14%), diarrhoea (10%), eye disor-
ders (10%), musculoskeletal disorders (10%) and elevated
liver enzymes (10%). Decreased appetite, weight loss and
anorexia occurred in 5%, 5% and 29% of patients, respec-
tively, and all were grade 1/2 in severity. Table III sum-
marises TEAEs overall and by dose level. Serious AEs
included upper-respiratory tract infection (n = 3), urinary
tract infection (n = 2), mastoid osteomyelitis (n = 2), upper
gastrointestinal (GI) bleeding (n = 1; deemed unrelated to
treatment with a platelet count of 167 9 109/l at the time of
Table I. Patient characteristics
Characteristic N = 21
Age
Median years (range) 64 (55–74)
≥65 years, n (%) 9 (43)
Sex, n (%)
Male 11 (52)
Female 10 (48)
Time since diagnosis, median (range), years 45 (16–117)
ECOG performance status, n (%)
0 13 (62)
1 8 (38)
ISS stage, n (%)
I 2 (10)
II 7 (33)
III 4 (19)
Unknown 8 (38)
Cytogenetic risk per IMWG, n (%)
High† 12 (57)
Deletion 17p 5 (24)
Standard 9 (43)
ECOG, Eastern Cooperative Oncology Group; IMWG, International
Myeloma Working Group; ISS, International Staging System.
†Defined per IMWG: t(4;14), del(17p), t(14;16), t(14;20), non-hyper-
diploidy and gain(1q).
Table II. Prior therapies
Prior therapy N = 21
Prior lines of therapy, median (range) 4 (2–10)
Prior PIs, n (%) 21 (100)
Carfilzomib 20 (95)
Bortezomib 20 (95)
Prior IMiDs, n (%) 21 (100)
Lenalidomide 20 (95)
Pomalidomide 17 (81)
Thalidomide 4 (19)
Other prior therapies, n (%) 20 (95)
Autologous stem-cell transplantation 20 (95)
Panobinostat 2 (10)
Daratumumab 1 (5)
Refractory to prior therapy, n (%) 21 (100)
Carfilzomib 20 (95)
Bortezomib 11 (52)
Pomalidomide 17 (81)
Lenalidomide 14 (67)
Dual-class refractory/quad-exposed† 17 (81)
Triple-class refractory/penta-exposed‡ 1 (5)
Refractory in last line of therapy, n (%) 21 (100)
Carfilzomib 13 (62)
Pomalidomide 11 (52)
Carfilzomib and pomalidomide 9 (43)
IMiD, immunomodulatory drug; PI, proteasome inhibitor.
†Refractory to a PI and an IMiD; exposed to bortezomib, lenalido-
mide, carfilzomib and pomalidomide.
‡Refractory to a PI, an IMiD and an anti-CD38 antibody; exposed
to bortezomib, lenalidomide, carfilzomib, pomalidomide and daratu-
mumab.
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the event), syncope (n = 1), deep vein thrombosis and pul-
monary embolism (n = 1), pain related to PD (n = 1) and
CHF with ejection fraction decrease (n = 1) considered
related to carfilzomib treatment in the patient with a history
of CHF and who retrospectively did not meet eligibility crite-
ria due to amyloidosis.
Dose modifications included new cycle delays for 11
(52%) patients, dose interruptions for 17 (80%) and dose
reductions for 13 (62%). Dose modification was needed for
selinexor in 15 (71%) patients, for carfilzomib in 11 (52%)
and for dexamethasone in 7 (33%). Treatment was discon-
tinued in two patients due to toxicity, which included a
patient with a urinary tract infection and the patient with
the pre-existing amyloidosis who experienced CHF (the latter
was considered treatment-related). Two patients experienced
progressive myeloma while treatment was on hold because of
AEs (pneumonia and cytopenias, respectively).
Response and treatment outcomes
Most patients achieved disease control after 1 cycle (CBR of
67% and ORR of 38%). For best response during the course
of treatment, the CBR was 71%, ORR was 48% and the
VGPR rate was 14% (Table IV). There were no CRs. The
patient with pre-existing amyloidosis who experienced a DLT
discontinued SKd prior to response evaluation; this was con-
sidered a non-response. For patients receiving the RP2D
(n = 13), CBR was 62% (90% CI: 036–083), ORR was 38%
(90% CI: 017–065) and the rate of VGPR was 15% (90%
CI: 003–041); two additional patients achieved SD. For
dual-refractory/quad-exposed patients (n = 17), the CBR was
76%, ORR was 53% and the VGPR rate was 18%, and for
patients who were refractory to carfilzomib in last line of
therapy (n = 13), the corresponding values were 77%, 62%
and 15%. The one patient who was tri-refractory/penta-ex-
posed achieved VGPR.
Durability and depth of responses are presented in Fig. 2.
The median duration of response for patients who achieved
≥MR and ≥PR were 29 and 34 months, respectively, for all
response-evaluable patients, 31 and 30 months for the
RP2D cohort, 28 and 33 months for the carfilzomib-refrac-
tory cohort and 31 and 30 months for the high-risk cohort.
Median PFS and OS were 37 and 224 months, respec-
tively, for all enrolled patients (Fig. 3), 37 and 224 months
Table III. Treatment-emergent adverse events
OverallN = 21
Dose Level 130 mg/m2
SEL;20/27 mg/m2
CFZ;20 mg DEXn = 5
Dose Level 2a40 mg
SEL;20/36 mg/m2
CFZ;20 mg DEXn = 3
Dose Level 2b†60 mg
SEL;20/27 mg/m2
CFZ;20 mg
DEXn = 13
All Grades Grades 3/4 All Grades Grades 3/4 All Grades Grades 3/4 All Grades Grades 3/4
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Haematological
Thrombocytopenia 17 (81) 15 (71) 4 (80) 4 (80) 3 (100) 3 (100) 10 (77) 8 (62)
Anaemia 15 (71) 7 (33) 4 (80) 2 (40) 2 (67) 0 9 (69) 5 (38)
Lymphopenia 11 (52) 7 (33) 3 (60) 2 (40) 1 (33) 1 (33) 7 (54) 4 (31)
Neutropenia 8 (38) 7 (33) 3 (60) 3 (60) 2 (67) 2 (67) 3 (23) 2 (15)
Non-haematological
Fatigue 17 (81) 3 (14) 4 (80) 3 (60) 3 (100) 0 10 (77) 0
Dyspnoea 11 (52) 1 (5) 3 (60) 0 3 (100) 1 (33) 5 (38) 0
Nausea 11 (52) 0 4 (80) 0 2 (67) 0 5 (38) 0
Diarrhoea 10 (48) 2 (10) 2 (40) 0 2 (67) 0 6 (46) 2 (15)
Musculoskeletal disorders 8 (38) 2 (10) 4 (80) 2 (40) 1 (33) 0 3 (23) 0
Eye disorders 7 (33) 2 (10) 3 (60) 1 (20) 2 (67) 0 2 (15) 1 (8)
Infection 6 (29) 5 (24) 1 (20) 1 (20) 1 (33) 1 (33) 4 (31) 3 (23)
Anorexia 6 (29) 0 3 (60) 0 0 0 3 (23) 0
Elevated liver and pancreatic enzymes 8 (38) 2 (10) 4 (80) 1 (20) 1 (33) 0 3 (23) 1 (8)
Vomiting 5 (24) 0 2 (40) 0 0 0 3 (23) 0
Oedema 4 (19) 1 (5) 2 (40) 1 (20) 1 (33) 0 1 (8) 0
Hyponatraemia 2 (10) 1 (5) 1 (20) 1 (20) 0 0 1 (8) 0
Confusion 2 (10) 1 (5) 1 (20) 1 (20) 0 0 1 (8) 0
Decreased appetite 1 (5) 0 0 0 1 (33) 0 0 0
Weight loss 1 (5) 0 0 0 1 (33) 0 0 0
Psychosis 1 (5) 1 (5) 1 (20) 1 (20) 0 0 0 0
Syncope 1 (5) 1 (5) 0 0 0 0 1 (8) 1 (8)
CFZ, carfilzomib; DEX, dexamethasone; SEL, selinexor.
†Recommended phase 2 dose.
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for the carfilzomib-refractory cohort and 30 and
224 months for the high-risk cohort. Median PFS and OS
were 35 and 224 months for the R2PD cohort and 37 and
232 months for the patients enrolled at Dose Level 1 or 2a.
Discussion
This study demonstrated the safety and tolerability of twice-
weekly SKd. Overall, the combination demonstrated manage-
able tolerability. Most patients required dose modifications,
but only two patients discontinued due to treatment-related
AEs. All patients received prophylactic megestrol acetate and
a 5-HT3 antagonist treatment to mitigate GI AEs. Additional
supportive measures, including growth factors and transfu-
sions, could be initiated by the investigator at any time dur-
ing treatment. The most common grade 3/4 AEs were
haematological in nature. GI and constitutional AEs were
common but were generally grade 1/2. Although carfilzomib
is associated with cardiac AEs (Chen et al, 2017b; Waxman
et al, 2018), only one patient (with a history of CHF and
underlying cardiac amyloidosis) experienced a cardiac AE
considered related to carfilzomib that led to treatment dis-
continuation. Based on the overall tolerability and the anti-
myeloma activity of the regimen, Dose Level 2b (twice-
weekly selinexor 60 mg with a standard twice-weekly dosing
of carfilzomib at 20/27 mg/m2, and twice-weekly dexametha-
sone at 20 mg) was selected for dose expansion, without
determination of the MTD. Based on the high rate of dose
reductions during our study and results from prior selinexor
studies (Bahlis et al, 2018; Chen et al, 2018; Vogl et al,
2018), we concluded that further dose escalation would
probably not be feasible. Dose Level 2b was clinically active
with a DLT rate <30% and selected as the RP2D.
The safety results with SKd were generally consistent with
safety outcomes from previous studies of selinexor in
RRMM, although the rates and severity of non-haematologi-
cal AEs, particularly GI events, were lower than anticipated
(Bahlis et al, 2018; Chen et al, 2018; Vogl et al, 2018). In the
phase II STORM study (N = 79 RRMM), the most common
grade 3/4 treatment-related AEs associated with twice-weekly
Sd (80 mg selinexor/20 mg dexamethasone) was thrombocy-
topenia (59%) (Vogl et al, 2018), an established toxicity of
selinexor because of its inhibition of megakaryocyte matura-
tion (Machlus et al, 2017). Other grade 3/4 treatment-related
AEs included anaemia (28%), neutropenia (23%) and lym-
phopenia (11%). Treatment-related non-haematological AEs
(any grade) included nausea (73%), fatigue (63%), decreased
appetite (49%), anorexia (49%), vomiting (44%), diarrhoea
(43%) and weight loss (33%); these were generally grade 1/2
in severity (Vogl et al, 2018).
Table IV. Response rates
Overall
Dose Level 130 mg/m2
SEL;20/27 mg/m2
CFZ;20 mg DEX
Dose Level 2a40 mg
SEL;20/36 mg/m2
CFZ;20 mg DEX
Dose Level 2b†60 mg
SEL;20/27 mg/m2
CFZ;20 mg DEX
Best response, n (%) N = 21 n = 5 n = 3 n = 13
Complete response 0 0 0 0
Very good partial response 3 (14) 1 (20) 0 2 (15)
Partial response 7 (33) 2 (40) 2 (67) 3 (23)
Minimal response 5 (24) 1 (20) 1 (33) 3 (23)
Stable disease 2 (10) 0 0 2 (15)
Progressive disease 3 (14) 1 (20) 0 2 (15)
Non-response‡ 1 (5) 0 0 1 (8)
ORR, n (%) 10 (48) 3 (60) 2 (67) 5 (38)
CBR, n (%) 15 (71) 4 (80) 3 (100) 8 (62)
Carfilzomib refractory in last line of therapy§, n (%) n = 13 n = 4 n = 2 n = 7
Very good partial response 2 (15) 1 (25) 0 1 (14)
ORR 8 (62) 3 (75) 2 (100) 3 (43)
CBR 10 (77) 3 (75) 2 (100) 5 (71)
Dual class refractory/quad exposed–, n (%) n = 17 n = 4 n = 3 n = 10
Very good partial response 3 (18) 1 (25) 0 2 (20)
ORR 9 (53) 3 (75) 2 (67) 4 (40)
CBR 13 (76) 4 (100) 3 (100) 6 (60)
CBR, clinical benefit rate (≥minimal response); CFZ, carfilzomib; DEX, dexamethasone; DLT, dose-limiting toxicity; IMiD, immunomodulatory
drug; ORR, objective response rate (≥partial response); PI, proteasome inhibitor; RP2D, recommended phase 2 dose; SEL, selinexor; VGPR, very
good partial response.
†Recommended phase 2 dose.
‡Patient was not evaluable due to a DLT that resulted in treatment discontinuation prior to response evaluation.
§Refractory to carfilzomib at ≥20 mg/m2 on twice-weekly schedule (i.e. on Days 1, 2, 8, 9, 15 and 16).
–Refractory to PI and IMiD/exposed to bortezomib, lenalidomide, carfilzomib and pomalidomide.
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In the phase I/II STOMP study (N = 42 RRMM), seli-
nexor was administered twice-weekly at 60 or 80 mg or
once-weekly at 80 or 100 mg in combination with Vd during
the dose-escalation stage; this was followed by a dose expan-
sion with the RP2D (Bahlis et al, 2018). The investigators
selected 100 mg once-weekly dose of selinexor as the RP2D,
and nearly all patients (39/42) received bortezomib 13 mg/
m2 weekly at treatment initiation rather than at the standard
twice-weekly dose schedule. The results suggested that the
rates for some treatment-related haematological and GI AEs
improved with once-weekly selinexor. The rate of grade 3/4
thrombocytopenia decreased from 69% during the dose-esca-
lation stage (60 or 80 mg selinexor twice-weekly/once-
weekly) to 31% with the RP2D, anaemia decreased from
25% to 4%, and grade 3 diarrhoea decreased from 13% to
4% (Bahlis et al, 2018).
The clinical activity of SKd is promising and compares
favourably with activity in studies of selinexor alone and seli-
nexor with dexamethasone (Sd) (Chen et al, 2018; Vogl et al,
2018). However, we also recognize the limitations of cross-
study comparisons and differences between study popula-
tions. The current study enrolled heavily pre-treated patients,
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all of which were refractory to their last line of therapy: 95%
were refractory to carfilzomib, 62% were refractory to carfil-
zomib in the last line of therapy and 57% had high-risk cyto-
genetics. In a phase I study of patients with RRMM (n = 81)
or Waldenstr€om macroglobulinaemia (n = 3), selinexor (3–
60 mg/m2 or fixed dose of 40 or 60 mg) showed modest
activity as a single agent with an ORR of 4% (n = 57) and a
CBR of 21%, which improved to 22% and 33%, respectively,
when twice-weekly selinexor (45 or 65 mg/m2) was combined
with 20 mg of dexamethasone (n = 27). At the 45 mg/m2
selinexor dose, the ORR for the combination was 50% (Chen
et al, 2018). In the STORM study, twice-weekly Sd (80/
20 mg) resulted in an ORR of 21% in patients with quad- or
penta-refractory RRMM (Vogl et al, 2018). Response rates
with SKd also appear consistent with those of SVd from the
STOMP study. ORR with SVd was 63% overall and 43% for
PI-refractory patients (n = 21) compared with 84% for PI-
nonrefractory patients (n = 19) (Bahlis et al, 2018).
The clinical activity of SKd also can be related to the
results from historical studies in RRMM (Berdeja et al, 2015;
Berenson et al, 2016, 2014; Dimopoulos et al, 2016b; Papa-
dopoulos et al, 2015; Richardson et al, 2013, 2014; San
Miguel et al, 2013; Shah et al, 2015; Siegel et al, 2012). Many
of these studies enrolled patients who had been previously
treated with bortezomib or lenalidomide with dexamethasone
to assess the efficacy and safety of carfilzomib and pomalido-
mide regimens. Response rates have ranged from 32% to
77% for pomalidomide or carfilzomib in combination with
dexamethasone (Berenson et al, 2016; Dimopoulos et al,
2016b; Papadopoulos et al, 2015; San Miguel et al, 2013) and
50% for the triplet of carfilzomib, pomalidomide and dexam-
ethasone (Shah et al, 2015).
While response rates and time to response in our study are
quite promising given the refractory status of the patient pop-
ulation, duration of response and PFS were shorter than antici-
pated in view of other selinexor studies. However, response
rates, duration of response and PFS in these other selinexor
studies were generally less robust in patients who were refrac-
tory to one of the drugs used in combination (Bahlis et al,
2018; Chen et al, 2017a; Gasparetto et al, 2017; White et al,
2017). Median PFS was 90 months for all evaluable patients
in the STOMP study but 61 months for PI-refractory patients,
compared with 178 months for PI-nonrefractory patients
(Bahlis et al, 2018). Further, OS in our study appeared pro-
longed at a median of 224 months when considering PFS
results. It is possible that SKd selected for less aggressive MM
clones at the time of progression, allowing for a durable
response with subsequent therapy (e.g., daratumumab), or
clones that were sensitive to subsequent treatment.
Observations from this study, particularly consistent and
rapid disease control (67% CBR in the first cycle), indicate
that SKd could be a ‘bridge’ to subsequent therapy, allowing
patients to at least transiently overcome resistance, restore
disease control and prepare for subsequent therapy. Further
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studies are needed to better understand these observations
and to determine the mechanism for loss of disease control
and to evaluate whether a different dosing or schedule with
SKd can improve durability of response. Based on observa-
tions from the STOMP trial (Bahlis et al, 2018), we are cur-
rently evaluating once-weekly SKd in carfilzomib-refractory,
carfilzomib/PI-na€ıve and non-refractory patient populations.
Other studies in RRMM are assessing selinexor in combina-
tion with liposomal doxorubicin (NCT02186834) and ixa-
zomib and dexamethasone (NCT02831686), and additional
cohorts from the STOMP trial have demonstrated the tolera-
bility and activity of twice- or once-weekly selinexor with
dexamethasone in combination with lenalidomide (SRd),
pomalidomide (SPd) or daratumumab (SDd) (Chen et al,
2017a; Gasparetto et al, 2017; White et al, 2017). The ongo-
ing phase III BOSTON study (NCT02831686) is evaluating
SVd in patients with RRMM who are PI-relapsed/-na€ıve.
With more patients receiving first- and second-line combi-
nations of PIs, IMiDs and monoclonal antibodies, it is
becoming more challenging to effectively treat patients in the
RRMM setting (Nooka et al, 2015). The addition of selinexor
to Kd demonstrated manageable safety and tolerability and
promising efficacy in a heavily pre-treated population of
patients with RRMM. Significant clinical activity was
observed in dual-refractory/quad-exposed patients, and in
patients who were carfilzomib-resistant in their last line of
therapy. Further studies are needed to understand the high
rate of response but relatively short response duration, and
to identify patients for whom SKd might serve as an effective
‘bridge’ regimen to subsequent therapies or as a line of ther-
apy that provides durable disease control.
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